Publications 2015
310.
Frantzi M, Latosinska A, Merseburger AS, Mischak H.
Recent progress in urinary proteome analysis for prostate cancer diagnosis and management
Expert Rev Mol Diagn
2015, 15(12):1539-54. Epub 2015 Oct 22.
309.
Seetho IW, Ramírez-Torres A, Albalat A, Mullen W, Mischak H, Parker RJ, Craig S, Duffy N, Hardy KJ, Burniston JG, Wilding JP.
Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment
Sleep Sci. 2015, 8(2):58-67. Epub 2015 Jul 17.
308.
Nkuipou-Kenfack E, Bhat A, Klein J, Jankowski V, Mullen W, Vlahou A, Dakna M, Koeck T, Schanstra JP, Zürbig P, Rudolph KL, Schumacher B, Pich A, Mischak H.
Identification of ageing-associated naturally occurring peptides in human urine
Oncotarget. 2015, 6(33):34106-17.
307.
Latosinska A, Vougas K, Makridakis M, Klein J, Mullen W, Abbas M, Stravodimos K, Katafigiotis I, Merseburger AS, Zoidakis J, Mischak H, Vlahou A, Jankowski V.
Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis
PLoS One. 2015, 10(9):e0137048.
306.
Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ.
Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes
Nephrol Dial Transplant. 2015, 30 Suppl 4:iv86-iv95.
305.
Jankowski J, Schanstra JP, Mischak H.
Body fluid peptide and protein signatures in diabetic kidney diseases
Nephrol Dial Transplant. 2015, 30 Suppl 4:iv43-iv53.
304.
Filip S, Vougas K, Zoidakis J, Latosinska A, Mullen W, Spasovski G, Mischak H, Vlahou A, Jankowski J.
Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine
PLoS One 2015 Jul 24;10(7):e0133773.
303.
Øvrehus MA, Zürbig P, Vikse BE, Hallan SI.
Urinary proteomics in chronic kidney disease: diagnosis and risk of progression beyond albuminuria
Clin Proteomics 2015, 12(1):21.
302.
Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, Neirynck N, Schanstra JP, Jankowski J, Mischak H, Argilés À, Vanholder R, Vlahou A, Klein J.
New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis
Nephrol Dial Transplant. 2015, 30(11):1842-52. Epub 2015 Jul 9.
301.
Vanmassenhove J, Van Biesen W, Glorieux G, Mischak H, Mullen W, Vanholder R, Metzger J.
FP179: Prediction of renal failure in sepsis patients by established CE-MS peptide marker panels
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii127.
300.
Siwy J, Pontillo C, Mullen W, Julien B, Novak J, Mischak H.
SaO039: Urinary proteomics identifies marker peptides in patients with ANCA-associated vasculitis (AAV), IgA nephropathy (IgAN), and Henoch-Schönlein purpura nephritis (HSPN)
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii40–iii41.
299.
Robinson S, Perco P, Husi H, Köck T, Mischak H, Jennings A, Monleón D, Ravassa S, Leenders J, Jankowski J, Chatzikyriakou C, Pieske B, Staessen J, Padmanabhan S, Zanchetti A, Dominiczak A, Delles C, EU-MASCARA Consortium.
PP.28.24: Integrative data analysis in the InGenious HyperCare cohort
Journal of Hypertension 2015, 33:e380.
298.
Pontillo C, Zürbig P, Schanstra JP, Ramírez-Torres A, Koeck T, Dakna M, Mischak H.
FP223: Urinary peptide-based prediction of progression from chronic kidney disease stage II to III
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii141.
297.
Pontillo C, Koeck T, Zürbig P, Schanstra JP, Mullen W, Mischak H.
FP220: Cardiovascular disease biomarkers overlap with chronic kidney disease biomarkers. A link for common molecular pathophysiology?
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii140.
296.
Nkuipou-Kenfack E, Ramírez-Torres A, Mullen W, Vlahou A, Koeck T, Schanstra JP, Zürbig P, Pich A, Mischak H.
FP268: Molecular similarity of renal ageing and CKD revealed by urinary proteomics
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii156–iii157.
295.
Metzger J, Mullen W, Mischak H, Klingele M.
FP191: Validation of a previously established urinary peptide marker model for early and accurate prediction of acute kidney injury in patients after cardiac surgery
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii131.
294.
Markoska K, Dakna M, Pontillo C, Filip S, Papadopoulos T, Neirynck N, Schepers E, Glorieux G, Schanstra JP, Zürbig P, Vanholder R, Vlahou A, Mischak H, Spasovski G.
FP227: Reduction of the eGFR expressed as percentage change of the slope per year may discriminate CKD patients with fast progression
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii142–iii143.
293.
Glorieux GL, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, Neirynck N, Schanstra J, Vlahou A, Jankowski J, Mischak H, Argiles A, Vanholder RC, Klein J.
FP279: High-resolution plasma proteome analysis identifies new changes in molecular mechanisms involved in chronic kidney disease
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii160–iii161.
292.
Gil RB, Heinzmann S, Wörmann K, Pontillo C, Vanholder R, Schmitt-Kopplin P, Mischak H.
FP292: Non-targeted metabolomics approaches for elucidation of novel diagnostic markers in chronic kidney disease
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii164–iii165.
291.
Filip S, Markoska K, Glorieux G, Papadopoulos T, Mullen W, Zoidakis J, Jankowski J, Schanstra JP, Vanholder R, Spasovski G, Mischak H, Vlahou A.
FP308: Urinary proteomics to decipher molecular pathophysiology of CKD progression
Nephrology Dialysis Transplantation 2015, 30(Suppl 3):iii170.
290.
Currie G, Flynn J, Lindhardt M, Mischak H, Rossing P, Delles C.
P3.3: The CKD273 urinary proteomic biomarker for early diagnosis of diabetic nephropathy does not indicate generalised subclinical vascular disease in normoalbuminuric type 2 diabetic patients
Artery Research 2015, 12(C):11.
289.
Currie G, Ravassa S, Mullen W, Mischak H, Lindhardt M, Rossing P, Delles C.
PP.33.31: Urinary proteomics and vascular disease in diabetic nephropathy
Journal of Hypertension 2015, 33(Suppl 1):e437.
288.
Currie G, Lindhardt M, Mischak H, Rossing P, Delles C.
PP.33.30: Baseline characteristics and determinants of CKD273 score in participants in the PRIORITY study: A single centre experience
Journal of Hypertension 2015, 33(Suppl 1):e436-e437.
287.
Milongo D, Bascands JL, Huart A, Esposito L, Breuil B, Moulos P, Siwy J, Ramírez-Torres A, Ribes D, Lavayssière L, Del Bello A, Muscari F, Alric L, Bureau C, Rostaing L, Schanstra JP, Kamar N.
Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation
Liver Int. 2015, 35(7):1893-901. Epub 2015 Jan 20.
286.
Zhang ZY, Thijs L, Petit T, Gu YM, Jacobs L, Yang WY, Liu YP, Koeck T, Zürbig P, Jin Y, Verhamme P, Voigt JU, Kuznetsova T, Mischak H, Staessen JA.
Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General Population
Hypertension 2015, 66(1):52-60. Epub 2015 May 11.
285.
Latosinska A, Frantzi M, Mullen W, Vlahou A, Makridakis M.
Targeting the proteome of cellular fractions: focus on secreted proteins
Methods Mol Biol. 2015, 1243:29-41.
284.
Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A.
Developing proteomic biomarkers for bladder cancer: towards clinical application
Nat Rev Urol. 2015, 12(6):317-330. Epub 2015 May 26.
283.
Pejchinovski M, Klein J, Ramírez-Torres A, Bitsika V, Mermelekas G, Vlahou A, Mullen W, Mischak H, Jankowski V.
Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine
Proteomics Clin Appl. 2015, 9(5-6):531-42.
282.
Mischak H
Pro: Urine proteomics as a liquid kidney biopsy: no more kidney punctures!
Nephrol. Dial. Transplant. 2015, 30 (4):532-537.
281.
Mischak H
Opponent's comments.
Nephrol Dial Transplant. 2015, 30(4):531-2.
280.
Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP.
Epidemiologic Design and Analysis for Proteomic Studies: A Primer on -Omic Technologies
Am J Epidemiol. 2015, 181(9):635-47. Epub 2015 Mar 19.
279.
Gleiss A, Dakna M, Mischak H, Heinze G.
Two-group comparisons of zero-inflated intensity values: the choice of test statistic matters
Bioinformatics 2015, 31(14):2310-7. Epub 2015 Mar 18.
278.
Brown CE, McCarthy NS, Hughes AD, Sever P, Stalmach A, Mullen W, Dominiczak AF, Sattar N, Mischak H, Thom S, Mayet J, Stanton AV, Delles C.
Urinary proteomic biomarkers to predict cardiovascular events
Proteomics Clin Appl. 2015, 9(5-6):610-7. Epub 2015 May 15.
277.
Nally JE, Mullen W, Callanan JJ, Mischak H, Albalat A.
Detection of urinary biomarkers in reservoir hosts of leptospirosis by capillary electrophoresis mass spectrometry
Proteomics Clin Appl. 2015, 9(5-6):543-51. Epub 2015 Apr 17.
276.
Mischak H, Delles C, Vlahou A, Vanholder R.
Proteomic biomarkers in kidney disease: issues in development and implementation
Nat Rev Nephrol. 2015, 11(4):221-32. Epub 2015 Feb 3.
275.
Pontillo C, Filip S, Borràs DM, Mullen W, Vlahou A, Mischak H.
CE-MS-based proteomics in biomarker discovery and clinical application
Proteomics Clin Appl. 2015, 9(3-4):322-34. Epub 2015 Mar 24.
274.
Pejchinovski M, Hrnjez D, Ramírez-Torres A, Bitsika V, Mermelekas G, Vlahou A, Zürbig P, Mischak H, Metzger J, Koeck T.
Capillary zone electrophoresis on-line coupled to mass spectrometry: a perspective application for clinical proteomics
Proteomics Clin Appl. 2015, 9(5-6):453-68. Epub 2015 Apr 7.
273.
Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder RJ.
Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides
J Am Soc Nephrol. 2015, 26(8):1999-2010. Epub 2015 Jan 14.
272.
Bhat A, Heinzel A, Mayer B, Perco P, Mühlberger I, Husi H, Merseburger AS, Zoidakis J, Vlahou A, Schanstra JP, Mischak H, Jankowski V.
Protein interactome of muscle invasive bladder cancer
PLoS One. 2015, 10(1):e0116404.
271.
Pejchinovski M, Siwy J, Metzger J, Mischak H, Jankowski V, Chapman AB, Kistler AD.
Urinary proteomic biomarkers, a powerful tool for prognosis of autosomal dominant polycystic kidney disease progression Nephrology Dialysis and Transplantation 2015, 30(Suppl3):iii80
270.
Berry M, Galinier M, Delmas C, Fournier P, Desmoulin F, Turkieh A, Mischak H, Mullen W, Barutaut M, Eurlings LW, Van Wijk S, Brunner-La Rocca HP, Caubere C, Butler J, Roncalli J, Evaristi MF, Cohen-Solal A, Seronde MF, Escamilla R, Ferrières J, Koukoui F, Smih F, Rouet P.
Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure
IJC Metab Endocr. 2015, 6: 5-12.
269.
Schanstra JP, Mischak H.
Proteomic urinary biomarker approach in renal disease: from discovery to implementation
Pediatr Nephrol. 2015, 30(5):713-25. Epub 2014 Mar 15.
268.
Silva S, Bronze M R, Figueira M, Siwy J, Mischak H, Combet E, Mullen W
Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study
Am J Clin Nutr. 2015, 101(1):44-54. Epub 2014 Nov 19.
267.
Bhat A, Dakna M, Mischak H.
Integrating proteomics profiling data sets: a network perspective
Methods Mol Biol. 2015, 1243:237-53.
266.
Stalmach A, Husi H, Mosbahi K, Albalat A, Mullen W, Mischak H.
Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids
Methods Mol Biol. 2015, 1243:187-205.